While rising institutional stakes highlight growing smart-money confidence in pharma, retail investors must weigh valuations, growth drivers, and regulatory risks before deciding whether to follow suit.
While rising institutional stakes highlight growing smart-money confidence in pharma, retail investors must weigh valuations, growth drivers, and regulatory risks before deciding whether to follow suit.
<iframe src="https://hindustansphere.com/embed/cluster/d31c7c74586734b65dc9c9fcd7ed9535f79771be" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FIIs and DIIs are piling into these four pharma stocks. Should you follow?"></iframe>
